GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, announced an unsecured $1,000,000 Revolving Loan Agreement with Bowery Consulting Group Inc. dated October 23, 2026. The loan carries a 12% annual interest rate and matures in 12 months, with advances subject to the lender's approval. The agreement also led to a major board reshuffle: five directors resigned, and three new directors nominated by the lender were appointed, reducing the board to five members. The new directors are Steven Brown, Tyler O’Brien, and Manpreet Uppal, all deemed independent under SEC and Nasdaq standards. O’Brien and Uppal join the Audit Committee alongside Dr. Robert McNally.
The financing provides GeoVax with working capital to support its operations, particularly its lead program GEO-MVA, an MVA-based vaccine targeting mpox and smallpox, which is advancing under an expedited regulatory pathway with a pivotal Phase 3 trial planned for late 2026. CEO David A. Dodd stated that the financing reinforces the balance sheet and provides needed working capital, and he welcomed the new directors, citing their diverse experience and leadership. He also thanked departing board members for their contributions. The announcement was first reported via NEWMEDIAWIRE.
However, the board changes raise governance concerns. The lender now has significant influence over the board, as all three new directors were nominated by Bowery Consulting Group. This shift could impact strategic decisions and oversight, potentially aligning the company more closely with the lender's interests. The loan's terms, including the lender's discretion over advances, also introduce financial risk. GeoVax's ability to draw funds is not guaranteed, and the 12% interest rate adds a fixed cost. The company's forward-looking statements highlight risks such as the lender's sole discretion over advances, potential default, and increased indebtedness limiting financial flexibility. For a clinical-stage biotech with no approved products, securing non-dilutive financing is crucial, but the governance concessions may be a trade-off. Investors will likely scrutinize the Form 8-K filing for further details on the loan agreement and director appointments.
GeoVax's pipeline includes Gedeptin®, a gene-directed enzyme prodrug therapy for head and neck cancer, and GEO-MVA for infectious diseases. The company maintains a global intellectual property portfolio and continues to evaluate strategic partnerships. For more information, visit www.geovax.com. The original release is available on www.newmediawire.com.
